Reported about 1 year ago
New CDC documents revealed that Moderna Inc.'s RSV vaccine efficacy dropped significantly in the second year, falling from 55% to 36% in patients with certain symptoms. This decline raises concerns about the vaccine's competitiveness compared to rival vaccines from Pfizer Inc. and GSK Plc. Moderna's updated data on its mRESVIA shot was presented during a CDC meeting. Following the news, Moderna shares experienced a significant decrease, marking their largest intraday decline since November.
Source: YAHOO